Dr. Kevin J. Scanlon's background includes: academic medicine, senior management in the pharmaceutical industry, CEO of start-up biotechnology companies and an angel investor. Some examples of his experiences includes the following:

• Dr. Kevin Scanlon is the Chairman of Pasadena Angels Investment Group. Kevin is also an executive member of the Los Angeles network of the Tech Coast Angels. These organizations support entrepreneurs with seed round investments for their novel technology. (Investment Community) Read his Entrepreneurial Economy article from the Technolink Association Newsletter in Adobe PDF Format.
• He is a faculty advisor for graduate business students involved in understanding the life science industry in the UCLA FEMBA Global Access Program (anderson.ucla.edu/gap.xml). (Teaching)
• Dr. Scanlon has worked with entrepreneurs, the investment community and international governments in Ireland, China and New Zealand to create an innovative culture around the intellectual property from their academic institutions. (Events)
• He was Co-Founder and former CEO of the cancer diagnostic company, Melanoma Diagnostics. The product, a six-gene assay that discriminates melanoma from moles, was sold to Myriad Genetics (Salt Lake City, Utah) in December 2010. (Entrepreneur). Download the official press release in Adobe PDF Format.
• As a Pharmaceutical Industry-Vice President at Berlex-Schering AG (Berlin, Germany), he was responsible for the company's international cancer program in the US, Europe and Asia. (Industry)
• Dr. Scanlon received his Ph.D. degree from the University of London in Molecular Biology and trained in Cancer Research at Yale Medical School. He was a Leukemia Society Scholar, awarded the Paul Martini Medical Research Prize in Cancer (Germany), was the past President of the International Society of Cell and Cancer Gene Therapy (England), was a participant at 400th Anniversary of Uppsala University (Sweden), is an advisor for the National Institute for Cellular Biotechnology (Ireland), Co-Editor/Co-Founder of the Nature journal "Cancer Gene Therapy", co-authored over 135 original scientific articles, edited nine medical books and has seven issued patents. (Science)